Anti-TdT/DNTT Antibody, clone 41A

DNA nucleotidylexotransferase (UniProt: P04053; also known as EC:2.7.7.31, Terminal addition enzyme, Terminal deoxynucleotidyltransferase, TdT, Terminal transferase) is encoded by the DNTT (also known as TDT) gene (Gene ID: 1791) in human. DNA polymerases are essential for replication, repair, and recombination of nucleic acid. In these processes, the polymerase extends a primer using a DNA template to guide each incorporation event. However, the requirement for using a template is not universal because cells possess terminal deoxynucleotidyl transferase (TdT) that has the ability to incorporate nucleotides in a template-independent manner using only single-stranded DNA as the nucleic acid substrate. TdT catalyzes the addition of deoxynucleotides to the 3′ hydroxy terminus of either double or single stranded DNA in a template-independent manner. Although TdT preferentially adds deoxynucleotides to 3′-extensions, tailing onto 5′ overhangs or blunt ended double strands of DNA can also be achieved. TdT is present in immature pre-B and pre-T cells where it inserts N-nucleotides to the V (D) J gene segment during rearrangements of genes. It plays a vital role in the development and variation of the immune system in vertebrates. TdT is commonly used for labeling DNA fragments and vectors with homopolymer tails and/or with modified deoxynucleotides, such as biotin-dNTPs, 32P-dNTPs, or ddNTP. Three alternative splice variants of TdT have been described in human. They are designated as TdTS (short), TdTL1 (long) and TdTL2 (long). TdTL1 and TdTL2 both localize in the nucleus, however, TdTL2 is expressed more abundantly in normal small lymphocytes compared to hTdTL1, which is readily detected in transformed lymphoid cell lines. Both long isoforms possess 3 →5 exonuclease activity for nucleotide removal whereas the short isoform performs nucleotide elongation of the coding ends during V(D)J recombination. Overexpression of TdTS or TdTL2 is reported to independently reduce the efficiency of V(D)J recombination, but the simultaneous overexpression of TdTS and TdTL2 can restore normal recombination frequencies. (Ref.: Gholami, S., et al. (2017). Adv Pharm Bull. 7(2); 215-220; Motea, EA., and Berdis, AJ. (2010). Biochim. Biophys. Acta. 804(5);1151-1166).

Clone 41A is a moue monoclonal antibody that detects human Terminal deoxynucleotidyltransferase (TdT).

Full-length recombinant human Terminal deoxynucleotidyltransferase (TdT).

Quality Control Testing

Evaluated by Western Blotting in Human thymus tissue lysate.

Western Blotting Analysis: A 1:250 dilution of this antibody detected TdT/DNTT in Human thymus tissue extracts.

Tested Applications

Immunofluorescence Analysis: A representative lot detected TdT/DNTT in Immunofluorescence application (McClory, S., et al. (2012). J Clin Invest. 122(4); 1403-15).

Immunohistochemistry (Paraffin) Analysis: A representative lot detected TdT/DNTT in Immunohistochemistry applications (McClory, S., et al. (2012). J Clin Invest. 122(4);1403-15).

Immunohistochemistry (Paraffin) Analysis: A 1:50 dilution from a representative lot detected TdT/DNTT in human thymus tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Anti-TdT/DNTT, clone 41A, Cat. No. MABE2043, is a mouse monoclonal antibody that detects TdT/DNTT and is tested for use in Immunofluorescence, Immunohistochemistry (Paraffin), and Western Blotting.

Purified mouse monoclonal antibody IgG2a in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Recommended storage: +2°C to +8°C.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.